EastGate Acquisitions Presents An Introduction To Its Self-Emulsifying Platform Delivery System For Enhancing Bioavailability Of Biologically Active Compounds

May 20, 2014

SALT LAKE CITY and TORONTO, May 20, 2014 /PRNewswire/ — EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aiming to make use of innovations in drug delivery for the development of improved novel formulations and alternative dosage forms for existing biologically active molecules. An introduction and a description of the company’s platform delivery and formulation technology is summarized below:

An analysis of currently marketed drugs identified a substantial number of compounds with poor bioavailability. Low absorption rates and poor bioavailability of a drug can necessitate an increase in the amount of drugs that patients receive. What advantages would be associated with a highly absorbable delivery system? Increased bioavailability could improve patient compliance, decrease side-effects, reduce treatment costs and offer a better quality of life.

EastGate Acquisitions’ technology platform provides an effective approach for increasing bioavailability and lowering the dosage of the active compound. How does EastGate achieve this? The company’s technology increases solubility of poorly soluble compounds in a proprietary self-emulsifying composition using a safe combination of known and approved excipients.

This technology platform can be applied to tranquilizers, narcotic antagonists, anti-inflammatory compounds, antibiotics, antifungal, vitamins, antioxidants, and brain protectants. As demonstrated by the video below, the Company’s technology may retain the active compound in the oil phase of nano-emulsions, thereby improving bioavailability and efficacy.


What are the other benefits of employing our self-emulsifying platform delivery system? Compared to other known methods of improving bioavailability, it:

    --  may allow incorporation of various biologically active compounds
        improving bioavailability and efficacy along with decreasing local
    --  only uses safe and well characterized and approved components and may
        reduce the need for prolonged regulatory and clinical programs
    --  may lessen requirements for long, expensive and time consuming
        toxicological studies
    --  is based on an easily scalable process.  A seamless scale-up from a 50
        kg to 1000 kg batch size was carried out for several products
    --  can be manufactured using standard pharmaceutical equipment
        --  increases intellectual property (IP) position: patent protection for
            the compositions, 'know-how' protection for the manufacturing
        --  may reduce the requirements for preclinical investigations and
            clinical testing, accelerate the clinical approval process, shorten
            marketing time, and simplify the process of product development.

The company has successfully applied its self-emulsifying delivery system to nutraceutical products with the initial goal of confirming its delivery capabilities. As a result, a line of nutraceuticals and other natural products have been created and are now available for marketing and distribution.

In the course of the development, the company applied its delivery technology to various pharmaceutical products. The company works in the fields of neurological disorders, infectious diseases and diabetes. Our primary focus is the treatment of acute epileptic seizures. The company’s technology, utilizing self-emulsifying delivery platform resulted in the creation of a prototype of the Lorazepam Spray. This intraoral spray can be used as an out-of-hospital treatment to prevent or treat acute seizures. The proprietary formulation is administered by a patient-friendly hand-held spray pump device. The patient himself, a family member, caregiver, or EMS personnel can easily operate the device to deliver a measured dose of Lorazepam, minimizing, or even potentially eliminating the need for hospitalization. The company is looking to pursue a fast-track approval for emergency use of this product.

“We have identified prosperous markets for which our self-emulsifying technology will have the greatest potential to be applied across a number of products, encompassing diverse sectors of the health industry” says Anna Gluskin, EastGate’s CEO. “Both the nutraceutical and pharmaceutical industries are consistently looking out for innovative products that increase patient compliance and reflect in higher profits.” Ms. Gluskin continues, “Our proprietary self-emulsifying technology confirms the saying ‘less is more’; i.e., use of smaller amount of active compound with better absorption rates and higher therapeutic efficacy.”

About EastGate Acquisitions Corporation

EastGate Acquisitions Corporation has locations in Salt Lake City, Utah and Toronto, Canada. It is a biotechnology company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. The Company’s model is based on a two-tier business approach that includes the development of novel pharmaceutical products and innovative dietary supplements. Both the pharmaceutical products and the natural dietary supplements are developed using highly effective modern technologies, and have further illustrated the importance of improving bioavailability of incorporated molecules. The company’s product candidates address various pharmaceutical markets, including neurological disorders such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions. EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate’s approach will be most beneficial for patient care. For more information, please visit the company’s website at www.EastGatePharmaceuticals.com.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Media Relations 1-647-692-0652

Email: information@eastgatepharmaceuticals.com

Text: ESAQ to 87804

SOURCE EastGate Acquisitions Corporation

Source: PR Newswire

comments powered by Disqus